patient subgroup...
Age < 65y (younger) Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mNSCLC - L1 - PDL1 positive, nivolumab plus ipilimumab , meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 0.79 [0.65, 0.96]< 1 0% 1 study (1/-) 99.1 % NA not evaluable crucial - progression or deaths (PFS) 0.82 [0.69, 0.97]< 1 0% 1 study (1/-) 98.9 % NA not evaluable important - objective responses (ORR) 1.31 [0.97, 1.76]> 1 0% 1 study (1/-) 96.1 % NA not evaluable non important - safety endpoints 00 STRAE (any grade) 1.96 [1.36, 2.83]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - STRAE (grade 3-4) 1.98 [1.32, 2.98]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - TRAE (any grade) 0.66 [0.46, 0.94]< 1 0% 1 study (1/-) 98.8 % NA not evaluable non important - TRAE (grade 3-4) 0.96 [0.72, 1.29]< 1 0% 1 study (1/-) 60.1 % NA not evaluable non important - TRAE leading to death (grade 5) 0.99 [0.28, 3.45]< 1 0% 1 study (1/-) 50.7 % NA not evaluable non important - TRAE leading to discontinuation (any grade) 3.13 [1.95, 5.03]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - TRAE leading to discontinuation (grade 3-4) 5.13 [2.63, 10.00]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - TRAE (grade 3-4) endpoints 00 Anaemia TRAE (grade 3-4) 0.11 [0.04, 0.28]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - Asthenia TRAE (grade 3-4) 1.24 [0.33, 4.65]< 1 0% 1 study (1/-) 37.5 % NA not evaluable non important - Constipation TRAE (grade 3-4) 0.99 [0.02, 50.01]< 1 0% 1 study (1/-) 50.2 % NA not evaluable non important - Decreased appetite TRAE (grade 3-4) 0.99 [0.25, 3.99]< 1 0% 1 study (1/-) 50.6 % NA not evaluable non important - Diarrhoea TRAE (grade 3-4) 3.00 [0.60, 14.96]< 1 0% 1 study (1/-) 9.1 % NA not evaluable non important - Fatigue TRAE (grade 3-4) 2.00 [0.60, 6.70]< 1 0% 1 study (1/-) 13.1 % NA not evaluable non important - Nausea TRAE (grade 3-4) 0.28 [0.06, 1.35]< 1 0% 1 study (1/-) 94.3 % NA not evaluable non important - Neutropenia TRAE (grade 3-4) 0.01 [0.00, 0.23]< 1 0% 1 study (1/-) 99.9 % NA not evaluable non important - Pruritus TRAE (grade 3-4) 3.97 [0.18, 88.42]< 1 0% 1 study (1/-) 19.5 % NA not evaluable non important - Rash TRAE (grade 3-4) 18.21 [1.05, 315.26]< 1 0% 1 study (1/-) 2.4 % NA not evaluable non important - Vomiting TRAE (grade 3-4) 0.10 [0.01, 0.76]< 1 0% 1 study (1/-) 98.6 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.